ClinicalTrials.gg

Program

ostarine

Also written as “GTx-024”, “Enobosarm” and “GTx-024 9mg”.

Its studies are mostly in Breast Neoplasms · Urinary Incontinence, Stress · Muscular Atrophy · Obesity · Triple Negative Breast Neoplasms, led by 3 companies.

Furthest: phase 3, since May 12, 201115 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GTx110 open or runningphase 3since May 12, 2011Apr 30, 2007none ahead
Veru31 open or runningphase 3since Apr 27, 2021Apr 27, 2021Oct 2027phase 2 · NCT07446998
Havah Therapeutics Pty10 open or runningphase 1since Aug 14, 2017Aug 14, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 30, 2007First study: phase 2 study in CachexiaNew to GTxGTx · NCT00467844 · 159 enrolled · United States, Canada
  2. May 12, 20112 phase 3 studies in Muscular AtrophyGTx · NCT01355497, NCT01355484
  3. Jun 7, 2012Phase 2 study in Breast NeoplasmsGTx · NCT01616758 · 22 enrolled · United States
  4. Feb 10, 2015Phase 2 study in Triple Negative Breast NeoplasmsGTx · NCT02368691 · 32 enrolled · United States
  5. Jun 2, 2015Phase 2 study in ER+ and AR+ Breast CancerGTx · NCT02463032 · 136 enrolled · United States
  6. Jan 13, 2016Phase 2 study in Urinary Incontinence, StressGTx · NCT02658448 · 19 enrolled · United States
  7. Apr 18, 2016Phase 2 study in ER+ and AR+ Breast CancerGTx · NCT02746328 · United States
  8. Aug 2, 2017Phase 2 study in Urinary Incontinence, StressGTx · NCT03241342 · 491 enrolled · United States
  9. Aug 14, 2017Havah Therapeutics Pty's first study: phase 1 study in Mammographic DensityNew to Havah Therapeutics PtyHavah Therapeutics Pty · NCT03264651 · 9 enrolled · Australia
  10. Apr 16, 2018Phase 2 study in Urinary Incontinence, StressGTx · NCT03508648 · United States
  11. May 30, 2018Phase 2 study in Urinary Incontinence, StressGTx · NCT03566290 · United States
  12. Apr 27, 2021Veru's first study: phase 3 study in Breast NeoplasmsNew to VeruVeru · NCT04869943 · 52 enrolled · United States, Poland, Spain and more
  13. Feb 20, 2024Phase 2 study in Muscular AtrophyVeru · NCT06282458 · 168 enrolled · United States
  14. Feb 25, 2026Phase 2 study in ObesityVeru · NCT07446998 · 239 enrolled · United States

Ahead

  1. Oct 2027Primary completion: phase 2 study in ObesityVeru · NCT07446998

TargetBeta

AR →read by rule
“Androgen Receptor modulator”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07446998Obesity · United States2Active, not recruitingVeruOct 2027239
NCT06282458Muscular Atrophy · United States2CompletedVeruApr 11, 2025168
NCT04869943Breast Neoplasms · United States, Poland, Spain and more3TerminatedVeruJan 9, 202452
NCT03566290Urinary Incontinence, Stress · United States2WithdrawnGTxSep 21, 20180
NCT03508648Urinary Incontinence, Stress · United States2WithdrawnGTxSep 21, 20180
NCT03264651Mammographic Density · Australia1CompletedHavah Therapeutics PtyMar 21, 20189
NCT03241342Urinary Incontinence, Stress · United States2CompletedGTxSep 21, 2018491
NCT02746328ER+ and AR+ Breast Cancer · United States2WithdrawnGTxFeb 20180
NCT02658448Urinary Incontinence, Stress · United States2CompletedGTxJun 201819
NCT02463032ER+ and AR+ Breast Cancer · United States2CompletedGTxMar 2019136
NCT02368691Triple Negative Breast Neoplasms · United States2TerminatedGTxSep 22, 201732
NCT01616758Breast Neoplasms · United States2TerminatedGTxJun 201422
NCT01355497Muscular Atrophy · United States3CompletedGTxMay 2013330
NCT01355484Muscular Atrophy · United States3CompletedGTxMay 2013321
NCT00467844Cachexia · United States, Canada2CompletedGTxSep 2008159

How it is read

Names in the registry

  • “GTx-024”, 9 entries
  • “Enobosarm”, 3 entries
  • “GTx-024 9mg”, 1 entry
  • “GTx-024 9 or 18 mg”, 1 entry
  • “GTx 024”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.